Patrik Jonsson (Eli Lilly): «Scienze della vita e terapie innovative. L’Italia investa sulla prevenzione»
L’executive vice presidente di Eli Lilly e presidente di Lilly International «Usa e Cina corrono, mentre l’Europa rischia di perdere competitività. Sesto Fiorentino sito modello»
Patrik Jonsson, executive vice president of Eli Lilly and president of Lilly International, warns that Europe risks losing competitiveness in the sciences of life and innovative therapies. He emphasizes that the continent must change its approach to access to therapies and the capacity of healthcare systems to invest in prevention.
Italy, despite having a strong scientific foundation, faces a critical crossroads. Europe, as a whole, is falling behind, with research and development investments declining to 30-31%, while Italy remains relatively slow in ensuring access to new drugs compared to other European countries. The United Kingdom, however, has taken a significant step by increasing the cost-effectiveness threshold and increasing spending on innovative drugs to 0.3-0.6% of GDP per capita, signaling strong support for innovation and making the country more attractive for research and development investments, clinical trials, and production.
Italy, with its strong scientific talent at sites like Sesto Fiorentino, must choose between embracing innovative treatments or staying on the current path where 80-85% of healthcare spending goes to acute care instead of early prevention of complications and comorbidities.
Written by urgent.news from Il Sole 24 Ore's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
